GLAUKOS CORP (GKOS) competitors & alternatives
Health Care · NYSE
GLAUKOS CORP (GKOS)'s top competitors and alternatives — its most similar public companies — include Johnson & Johnson (JNJ), SIGHT SCIENCES INC (SGHT), HARROW INC (HROW), Outlook Therapeutics, Inc. (OTLK), STAAR SURGICAL (STAA), Cooper Companies (The) (COO), EYEPOINT INC (EYPT), LENZ THERAPEUTICS INC (LENZ), ANI PHARMACEUTICALS INC (ANIP), TARSUS PHARMACEUTICALS INC (TARS), Abbott Laboratories (ABT) and SPYGLASS PHARMA INC SHS (SGP). These are GLAUKOS CORP's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GKOS competitors & alternatives
-
Johnson & JohnsonJNJHealth Care
A global healthcare leader spanning pharmaceuticals, medical devices, and consumer health products, with a portfolio spanning acute care, oncology, immunology,…
$255.63 (as of 2026-07-22) · market cap $614.6B
-
SIGHT SCIENCES INCSGHTHealth Care
Sight Sciences develops minimally invasive interventional devices for glaucoma and dry eye, targeting ophthalmology markets through reimbursement-focused…
$5.03 (as of 2026-07-22) · market cap $274M
-
HARROW INCHROWHealth Care
A specialty ophthalmic pharmaceuticals company developing and commercializing a broad portfolio of branded drugs and biosimilars for front and back-of-eye…
$42.83 (as of 2026-07-22) · market cap $1.6B
-
Outlook Therapeutics, Inc.OTLKHealth Care
Outlook Therapeutics develops ophthalmic biologics for retinal diseases, with its lead product LYTENAVA (bevacizumab gamma) approved in Europe and under FDA…
$1.34 (as of 2026-07-22) · market cap $212M
-
STAAR SURGICALSTAAHealth Care
STAAR Surgical designs and manufactures implantable collamer lenses (ICLs) for refractive vision correction, offering reversible alternatives to corneal…
$24.71 (as of 2026-07-22) · market cap $1.2B
-
Cooper Companies (The)COOHealth Care
A global medical device leader operating at the intersection of vision care and women's health through its CooperVision and CooperSurgical divisions.
$70.50 (as of 2026-07-22) · market cap $13.9B
-
EYEPOINT INCEYPTHealth Care
EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular…
$12.66 (as of 2026-07-22) · market cap $1.1B
-
LENZ THERAPEUTICS INCLENZHealth Care
LENZ Therapeutics is a commercial-stage ophthalmic company that developed VIZZ, the first FDA-approved, once-daily aceclidine-based eye drop for the treatment…
$5.34 (as of 2026-07-22) · market cap $167M
-
ANI PHARMACEUTICALS INCANIPHealth Care
A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and…
$77.61 (as of 2026-07-22) · market cap $1.8B
-
TARSUS PHARMACEUTICALS INCTARSHealth Care
Tarsus Pharmaceuticals commercializes XDEMVY, the first FDA-approved treatment for Demodex blepharitis, with a pipeline of lotilaner-based therapies for ocular…
$57.58 (as of 2026-07-22) · market cap $2.5B
-
Abbott LaboratoriesABTHealth Care
Abbott Laboratories is a diversified healthcare giant providing a broad portfolio of diagnostic systems, medical devices, nutritional products, and established…
$100.57 (as of 2026-07-22) · market cap $175.1B
-
SPYGLASS PHARMA INC SHSSGPHealth Care
Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
$20.54 (as of 2026-07-22) · market cap $682M
Not quite? Describe exactly what you want →
Peers are GLAUKOS CORP's closest public companies by shared sub-industry, sector and business themes. See the full profile: GLAUKOS CORP (GKOS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.